• 1
    Arlt VM,Stiborova M,vom Brocke J,Simoes ML,Lord GM,Nortier JL,Hollstein M,Phillips DH,Schmeiser HH. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 2007; 28: 225361.
  • 2
    Stiborova M,Frei E,Arlt VM,Schmeiser HH. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res 2008; 658: 5567.
  • 3
    International Agency for Research on Cancer.Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monographs Evaluation of Carcinogenic Risks in Humans, Vol. 82. Lyon, France: IARC, 2002.
  • 4
    Nortier JL,Martinez MC,Schmeiser HH,Arlt VM,Bieler CA,Petein M,Depierreux MF,De Pauw L,Abramowicz D,Vereerstraeten P,Vanherweghem JL. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342: 168692.
  • 5
    Grollman AP,Shibutani S,Moriya M,Miller F,Wu L,Moll U,Suzuki N,Fernandes A,Rosenquist T,Medverec Z,Jakovina K,Brdar B, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 2007; 104: 1212934.
  • 6
    Hranjec T,Kovac A,Kos J,Mao W,Chen JJ,Grollman AP,Jelakovic B. Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat Med J 2005; 46: 11625.
  • 7
    Liu Z,Hergenhahn M,Schmeiser HH,Wogan GN,Hong A,Hollstein M. Human tumor TP53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized TP53 gene. Proc Natl Acad Sci USA 2004; 101: 29638.
  • 8
    Liu Z,Muehlbaer K-R,Schmeiser HH,Hergenhahn M,Belharazem D,Hollstein MC. P53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res 2005; 65: 25837.
  • 9
    Luo JL,Yang Q,Tong WM,Hergenhahn M,Wang ZQ,Hollstein M. Knock-in mice with a chimeric human/murine TP53 gene develop normally and show wild-type TP53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 2001; 20: 3208.
  • 10
    Reinbold M,Luo JL,Nedelko T,Jerchow B,Murphy ME,Whibley C,Wei Q,Hollstein M. Common tumour TP53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene 2008; 27: 278894.
  • 11
    Pietsch EC,Humbey O,Murphy ME. Polymorphisms in the TP53 pathway. Oncogene 2006; 25: 160211.
  • 12
    Petitjean A,Mathe E,Kato S,Ishioka C,Tavtigian SV,Hainaut P,Olivier M. Impact of mutant TP53 functional properties on TP53 mutation patterns and tumor phenotype: lessions from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 6229.
  • 13
    Feldmeyer N,Schmeiser HH,Muehlbauer K,Belharazem D,Knyazev Y,Nedelko T,Hollstein M. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human TP53 sequences. Mutation Res 2006; 608: 1638.
  • 14
    Vom Brocke J,Schmeiser HH,Reinbold M,Hollstein M. MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 2006; 27: 21417.
  • 15
    Olivier M,Eeles R,Hollstein M,Khan MA,Harris CC,Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 60714.
  • 16
    Kato S,Han S-Y,Liu w,Otsuka K,Shibata H,Kanamaru R,Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100: 84249.
  • 17
    Lord GM,Hollstein M,Arlt VM,Roufosse C,Pusey CD,Cook T,Schmeiser HH. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 2004; 43: e11e17.
  • 18
    Palma N,Cinelli S,Sapora O,Wilson SH,Dogliotti E. Ochratoxin A-induced mutagenesis in mammalian cells is consistent with the production of oxidative stress. Chem Res Toxicol 2007; 20: 10317.